On November 11, INNOVENT BIO fell 3.06% in Regular Trading, trading at HK$85.55, with turnover of HK$205 million.
The most relevant recent catalyst in public information was the company’s November 9 announcement that its Phase III CREDIT-5 study met the primary endpoint for Sintbilo as a first-line monotherapy in non-familial hypercholesterolemia and mixed hyperlipidemia, but the latest market alert indicates the stock turned lower after that positive update.
Background data show the 198-patient China study delivered significant LDL-C reduction versus placebo at week 12, with favorable safety and no severe or serious treatment-emergent adverse events or new safety signals disclosed. The product is described as the first domestic PCSK9 antibody launched in China and had already been added to the national reimbursement drug list effective January 1, supporting its commercial positioning. Earlier, the company also disclosed third-quarter product revenue of more than RMB4.7 billion, up more than 40% year over year.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments